Format

Send to

Choose Destination
Curr Opin Immunol. 2012 Apr;24(2):217-24. doi: 10.1016/j.coi.2011.12.011. Epub 2012 Jan 12.

Modulation of GITR for cancer immunotherapy.

Author information

1
Swim Across America Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY, USA.

Abstract

Modulation of co-inhibitory and co-stimulatory receptors of the immune system has become a promising new approach for immunotherapy of cancer. With the recent FDA approval of CTLA-4 blockade serving as an important proof of principal, many new targets are now being translated into the clinic. Preclinical research has demonstrated that targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor related gene (GITR), a member of TNF receptor superfamily, by agonist antibodies or natural ligand, can serve as an effective anti-tumor therapy. In this review, we will cover this research and the rationale that has led to initiation of two phase 1 clinical trials targeting GITR as a new immunotherapeutic approach for cancer.

PMID:
22245556
PMCID:
PMC3413251
DOI:
10.1016/j.coi.2011.12.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center